Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Long Term Follow-up of Rituximab for Anti-Myelin-Associated Glycoprotein Demyelinating Polyneuropathy in IgM Gammopathies: Clinical, Hematological and Neurophysiological Correlations

Enrico Amaducci, Irene Dogliotti, Claudio Vitale, Irene Schiavetti, Michele Clerico, Giulia Benevolo, Mattia Parisi, Davide Bertuzzo, Veronica Peri, Federica Cavallo, Simone Ragaini, Chiara Consoli, Mariapia Pironti, Benedetto Bruno, Leonardo Lopiano, Alessandra Di Liberto, Daniela Drandi, Bruno Ferrero, Simone Ferrero

Blood (2024) 144 (Supplement 1): 6877.

https://doi.org/10.1182/blood-2024-203332

Published: 2024

Journal Articles

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 339.

https://doi.org/10.1182/blood-2024-194832

Published: 2024

Journal Articles

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial ( ECWM-2 ) of the European Consortium for Waldenström's Macroglobulinemia

Blood (2024) 144 (Supplement 1): 859.

https://doi.org/10.1182/blood-2024-200604

Published: 2024

Journal Articles

Determining the Mutational Landscape of Waldenström's Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström's Macroglobulinemia

Philipp Nakov, Daniela Drandi, Lisa Marie Kaiser, Dajana Kaszynski, Alexander Grunenberg, Jasmin Mark, Elke Runge, Meletios Dimopoulos, Efstathios Kastritis, Tina Bagratuni, Christian Buske, Christiane Pott, Simone Ferrero, Mouhamad Khouja

Blood (2024) 144 (Supplement 1): 4352.

https://doi.org/10.1182/blood-2024-204645

Published: 2024

Journal Articles

Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Blood (2024) 144 (Supplement 1): 4390.

https://doi.org/10.1182/blood-2024-197940

Published: 2024

Journal Articles

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2024) 144 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2024-203004

Published: 2024

Journal Articles

Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial

Blood (2024) 144 (Supplement 1): 3297.

https://doi.org/10.1182/blood-2024-198382

Published: 2024

Journal Articles

MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Blood (2023) 142 (Supplement 1): 4373.

https://doi.org/10.1182/blood-2023-181813

Published: 2023

Journal Articles

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Blood (2023) 142 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2023-182946

Published: 2023

Journal Articles

Prospective Evaluation of Minimal Residual Disease in Waldenström Macroglobulinemia across Different Tissues and Treatments: Results of the “BIO-WM” Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 1621.

https://doi.org/10.1182/blood-2023-181731

Published: 2023

Journal Articles

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Blood (2022) 140 (12): 1378–1389.

https://doi.org/10.1182/blood.2021014270

Published: 2022

Includes: Supplemental data

Journal Articles

Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2021) 138 (Supplement 1): 48.

https://doi.org/10.1182/blood-2021-148424

Published: 2021

Journal Articles

Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137119

Published: 2020

Journal Articles

Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification

Blood (2018) 132 (Supplement 1): 920.

https://doi.org/10.1182/blood-2018-99-114442

Published: 2018

Journal Articles

Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory WaldenstrÃ¶m Macroglobulinemia Patients

Blood (2018) 132 (Supplement 1): 1607.

https://doi.org/10.1182/blood-2018-99-114023

Published: 2018

Journal Articles

Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma

Blood (2017) 130 (Supplement 1): 2742.

https://doi.org/10.1182/blood.V130.Suppl_1.2742.2742

Published: 2017

Journal Articles

Highly Sensitive Droplet Digital PCR for MYD88 L265P Mutation Detection and Minimal Residual Disease Monitoring in Waldenström Macroglobulinemia

Daniela Drandi, Elisa Genuardi, Paola Ghione, Daniele Grimaldi, Barbara Mantoan, Marina Ruggeri, Daniela Barbero, Luigia Monitillo, Marika Vasta, Eleonora Marzanati, Giulia Verardo, Paola Omedè, Federica Cavallo, Mario Boccadoro, MD, Marco Ladetto, Simone Ferrero

Blood (2015) 126 (23): 2645.

https://doi.org/10.1182/blood.V126.23.2645.2645

Published: 2015

Journal Articles

Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients

Lenka Kubiczkova-Besse, Lenka Sedlarikova, Fedor Kryukov, Lenka Radova, PhD, Jana Nekvindova, Pavel Nemec, Daniela Drandi, Simona Caltagirone, Paola Omedè, PhD, Marta Krejci, As Prof, MD PhD, Zdenek Adam, prof, MD PhD, Ludek Pour, Doc, MD PhD, Sabina Sevcikova, PhD, Antonio Palumbo, MD, Mario Boccadoro, Roman Hajek, Prof, MD PhD

Blood (2014) 124 (21): 2043.

https://doi.org/10.1182/blood.V124.21.2043.2043

Published: 2014

Journal Articles

Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma

Benedetto Bruno, MD PhD, Simone Ferrero, MD, Daniela Drandi, Moreno Festuccia, MD, Francesca Patriarca, MD, Nicola Mordini, MD, Silvia Cena, PhD, Daniela Barbero, PhD, Luigia Monitillo, PhD, Federica Ferrando, MD, Lucia Brunello, MD, Renato Fanin, MD, Paola Ghione, MD, Paola Omedè, PhD, Luisa Giaccone, MD PhD, Antonio Palumbo, MD, Roberto Passera, PhD, Mario Boccadoro, MD, Marco Ladetto, MD

Blood (2014) 124 (21): 44.

https://doi.org/10.1182/blood.V124.21.44.44

Published: 2014

NARROW

Long Term Follow-up of Rituximab for Anti-Myelin-Associated Glycoprotein Demyelinating Polyneuropathy in IgM Gammopathies: Clinical, Hematological and Neurophysiological Correlations

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial ( ECWM-2 ) of the European Consortium for Waldenström's Macroglobulinemia

Determining the Mutational Landscape of Waldenström's Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström's Macroglobulinemia

Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial

MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Prospective Evaluation of Minimal Residual Disease in Waldenström Macroglobulinemia across Different Tissues and Treatments: Results of the “BIO-WM” Trial of the Fondazione Italiana Linfomi (FIL)

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL)

Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial

Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification

Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory WaldenstrÃ¶m Macroglobulinemia Patients

Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma

Extracellular Vesicles as Potential Biomarker for Acute Graft-Versus-Host-Disease

Highly Sensitive Droplet Digital PCR for MYD88 L265P Mutation Detection and Minimal Residual Disease Monitoring in Waldenström Macroglobulinemia

Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients

Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only